Bo Kang et al., 2022-11-23: Preclinical colorectal cancer study of a new IGF-1R inhibitor (PB-020) combined with mebendazole and, separately, with anti-PD-1; both combinations suppressed PI3K/AKT signalling.
Moreover, the PB-020/anti-PD-1 combination synergistically blocked CRC propagation in the MC38 murine colon carcinoma model.
Bo Kang et al., 2022-11-23: Preclinical colorectal cancer study of a new IGF-1R inhibitor (PB-020) combined with mebendazole and, separately, with anti-PD-1; both combinations suppressed PI3K/AKT signalling. Study type: cell lines plus mouse xenograft and MC38 syngeneic models. N: not stated in the abstract. Country: China (Zhejiang University). Dose: not stated in the abstract text captured. Funder: National Natural Science Foundation of China (32170739, 31601103); National Key R&D Program of China (2016YFA0100303, 2016YFA0101201). Declared conflicts: 'The authors declare that they have no competing interests.' PARTLY AND WITH A CORRECTION: the checkpoint-inhibitor arm in this paper is PB-020 plus anti-PD-1, not mebendazole plus anti-PD-1. The paper supports mebendazole-plus-targeted-therapy combinations, and does not itself test mebendazole with a checkpoint inhibitor. Study type: animal.
